ALOX5AP: Arachidonate 5-lipoxygenase-activating protein
Required for leukotriene biosynthesis by ALOX5 (5- lipoxygenase).
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on ALOX5AP, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Fiboflapon | Phase 3 | GSK | Small molecule | Inhibitor5-lipoxygenase activating protein inhibitor | 0 |
| Veliflapon | Phase 3 | deCODE genetics | Small molecule | Inhibitor5-lipoxygenase activating protein inhibitor | 0 |
- Bipolar disorder0.39
- Ischemic stroke0.38
- Ulcerative colitis0.31
- Inflammatory bowel disease0.31
- Asthma0.31
- Ankylosing spondylitis0.14
- Abnormality of the skeletal system0.11
- Ovarian dysfunction0.09
- Acute myeloid leukemia0.08
- Glioma0.08
- Central nervous system cancer0.08
- Ovarian carcinoma0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4550, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P20292, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets